RecruitingNCT06526442

MRE for Diagnosis of Pancreatic Masses

Experimental and Clinical Study of Three-dimensional Magnetic Resonance Elastography to Evaluate Pancreatic Cancer and Interstitial Fibrosis

Sponsor

Yu Shi

Enrollment

200 participants

Start Date

Oct 9, 2020

Study Type

OBSERVATIONAL

Conditions

Magnetic Resonance Imaging Pancreatic Neoplasm

Summary

Pancreatic ductal adenocarcinoma (PDAC) accounts for 85-95% of pancreatic cancer and is one of the deadliest tumors in the world, with a survival rate of less than 8%, and identifying key prognostic or predictive factors facilitates risk stratification and prospective assessment in clinical trials. The extracellular matrix (ECM) surrounding PDAC often exhibits a large number of interstitial fibrosis, which is closely related to the formation, development and metastasis of PDAC. High order three-dimensional MR elastography (3D-MRE) allows non-invasive measurements of sheer stiffness in normal pancreas and pancreatic lesions. However, there are no reports about the application of MRE imaging biomarkers to predict the prognosis of PDAC at home and abroad.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is using a special type of MRI technique called magnetic resonance elastography (MRE) to study the stiffness and mechanical properties of pancreatic tumors. Researchers hope this could improve the diagnosis and surgical planning for pancreatic ductal adenocarcinoma (PDAC), one of the most serious types of pancreatic cancer. **You may be eligible if...** - You are 18 or older - You have a confirmed diagnosis of pancreatic ductal adenocarcinoma (PDAC) based on surgical biopsy - You do not have a history of cancer elsewhere in the body - You have not had pre-operative bile duct drainage - You have at least 3 months of follow-up after surgery (or at least 6 months total) **You may NOT be eligible if...** - Your tumor tissue cannot be re-reviewed - Your MRE imaging data were of unacceptable quality (e.g., movement during the scan) - Your tumor diameter is less than 1.0 cm - You withdrew or dropped out of follow-up Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.